Revelation Biosciences (REVB) Stock Price, News & Analysis

Company Overview

Revelation Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. It engages in developing therapeutic product candidates, including GEM-SSI, a potential therapy for the prevention and treatment of surgical sit infection; GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease. The company was founded in 2020 and is based in San Diego, California.

Key Stats

• Today's Range: $0.73 to $0.76
• 50-Day Range: $0.72 to $1.04
• 52-Week Range: $0.70 to $25.26
• Volume: 116,696 shs
• Average Volume: 1.34 million shs
• Market Capitalization: $3.24 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

REVB Stock Analysis - Frequently Asked Questions

How have REVB shares performed this year?

Revelation Biosciences' stock was trading at $15.0210 at the beginning of the year. Since then, REVB shares have decreased by 95.0% and is now trading at $0.7550.
View the best growth stocks for 2024 here.

How were Revelation Biosciences' earnings last quarter?

Revelation Biosciences, Inc. (NASDAQ:REVB) announced its quarterly earnings data on Tuesday, January, 29th. The company reported $619.50 earnings per share (EPS) for the quarter, missing the consensus estimate of $640.50 by $21.00. The firm earned $22.79 million during the quarter, compared to analysts' expectations of $22.20 million.

When did Revelation Biosciences' stock split?

Shares of Revelation Biosciences reverse split on the morning of Thursday, January 25th 2024. The 1-30 reverse split was announced on Thursday, January 25th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, January 25th 2024. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

How do I buy shares of Revelation Biosciences?

Shares of REVB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Revelation Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Revelation Biosciences investors own include Predictive Oncology (POAI), Ford Motor (F), Wells Fargo & Company (WFC), Wayfair (W), Abbott Laboratories (ABT), JPMorgan Chase & Co. (JPM) and Bank of America (BAC).

Company Calendar

• Last Earnings: 1/29/2019
• Today: 11/23/2024
• Fiscal Year End: 12/31/2024
• Next Earnings (Estimated): 3/28/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:REVB
• CUSIP: N/A
• CIK: 1810560
• Web: www.revbiosciences.com
• Phone: 650-800-3717
• Fax: N/A
• Employees: 10
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($16.76)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-120,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -193.51%
• Return on Assets: -84.00%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.64
• Quick Ratio: 1.64

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.62 per share
• Price / Book: 1.22

Miscellaneous

• Outstanding Shares: 4,290,000
• Free Float: 4,284,000
• Market Cap: $3.24 million
• Optionable: Not Optionable
• Beta: 0.15